A Phase 2 interventional study of LUM/IVA and LUM/IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 5 sites in Germany. Open to participants aged 2 Years to 5 Years. Per ClinicalTrials.gov, last updated 2022-11-02.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing lumacaftor in Cystic Fibrosis — none open to participants now, none under way, none of them phase 3. lumacaftor · Cystic Fibrosis.
Among the 20 studies testing lumacaftor in Cystic Fibrosis, this one is the 15th largest by enrollment, is one of 2 that started in 2018, is one of 4 in phase 2, and was the 19th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →None of the 20 studies testing lumacaftor in Cystic Fibrosis is open now. The open studies under Cystic Fibrosis, anywhere →
lumacaftor: first FDA approval 2015 (ORKAMBI), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 2 Years to 5 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2018.
This study's enrollment of 51 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 66 across the 20 interventional studies. Of the 20 that completed or were terminated, 15 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 20 have an industry lead sponsor. The 1 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 55 (51%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 77th largest by enrollment of the 116 interventional ones that give a count, is one of 13 that started in 2018, is one of 21 in phase 2, and was the 81st registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing lumacaftor in Cystic Fibrosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
This study will explore the impact of lumacaftor/ivacaftor (LUM/IVA) on disease progression in subjects aged 2 through 5 years with cystic fibrosis (CF), homozygous for F508del (F/F).
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo matched to LUM/IVA in placebo-controlled period for 48 weeks.
Drug: Placebo
Participants weighing less than (\<)14 kilograms (kg) at screening received LUM 100 milligrams (mg)/IVA 125 mg fixed-dose combination (FDC) every 12 hours (q12h) in placebo-controlled period for 48 weeks. Participants weighing greater than or equals to (\>=)14 kg at screening received LUM 150 mg/IVA 188 mg FDC q12h in placebo-controlled period for 48 weeks.
Drug: LUM/IVA
Participants who received either placebo or LUM/IVA in placebo-controlled period administered LUM/IVA (either LUM 100 mg/IVA 125 mg FDC q12h or LUM 150 mg/IVA 188 mg FDC q12h as per their body weight for participants \<6 years of age at week 48 and LUM 200 mg/IVA 250 mg FDC q12h regardless of their body weight for participants \>=6 years of age at week 48) in open-label period for 48 weeks.
Drug: LUM/IVA
Drug pages: Lumacaftor · Ivacaftor
FDC tablets or granules for oral administration.
Also known as: Lumacaftor/Ivacaftor, VX-809/VX-770
Drug pages: Lumacaftor · Ivacaftor
FDC granules for oral administration.
Also known as: Lumacaftor/Ivacaftor, VX-809/VX-770
Placebo matched to LUM/IVA for oral administration.
Part 1: Absolute Change From Baseline in MRI Global Chest Score at Week 48
MRI scans assessed semi-quantitatively via a standardized chest MRI scoring system. Each participant had 6 lobes scored using 7 scoring parameters:1) Bronchiectasis/wall thickening 2) Mucus plugging 3) Abscesses/sacculations 4) Consolidations 5) Special findings 6)Mosaic pattern 7) Perfusion abnormalities. For each of 7 parameter, there were scores of 6 lobes (score of each lobe : 0= normal value, 1 = \<50% of lobe involved and 2 = \>=50% of lobe involved). MRI global score was calculated as sum of parameters 1 to 7. MRI total score is ranged from 0-84. Higher score indicate more lobe involvement.
Time frame: From Baseline at Week 48
Part 1: Absolute Change in Lung Clearance Index2.5 (LCI2.5) Through Week 48
LCI2.5 represents the number of lung turnovers required to reduce the end-tidal inert gas concentration to 1/40th of its starting value.
Time frame: From Baseline Through Week 48
Part 1: Absolute Change in Weight-for-age Z-score at Week 48
The z-score is a statistical measure to describe whether a value was above or below the standard. A z-score of 0 is equal to the standard. Lower numbers indicate values lower than the standard and higher numbers indicate values higher than the standard.
Time frame: From Baseline at Week 48
Part 1: Absolute Change in Stature-for-age Z-score at Week 48
The z-score is a statistical measure to describe whether a value was above or below the standard. A z-score of 0 is equal to the standard. Lower numbers indicate values lower than the standard and higher numbers indicate values higher than the standard.
Time frame: From Baseline at Week 48
Part 1: Absolute Change in Body Mass Index (BMI)-For-age Z-score at Week 48
BMI was defined as weight in kilogram (kg) divided by squared height in meters (m\^2). The z-score is a statistical measure to describe whether a value was above or below the standard. A z-score of 0 is equal to the standard. Lower numbers indicate values lower than the standard and higher numbers indicate values higher than the standard.
Time frame: From Baseline at Week 48
This study was planned in 2 parts: Part 1 (Placebo-controlled Period) and Part 2 (Open-label Period). The primary and secondary efficacy analyses were planned for only Part 1.
| Milestone | Part 1: Placebo | Part 1: LUM/IVA | Part 2: Overall LUM/IVA |
|---|---|---|---|
| Started | 16 | 35 | 0 |
| Completed | 16 | 33 | 0 |
| Not completed | 0 | 2 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 |
| Withdrew: Withdrawal of consent (not due to ae) | 0 | 1 | 0 |
| Milestone | Part 1: Placebo | Part 1: LUM/IVA | Part 2: Overall LUM/IVA |
|---|---|---|---|
| Started | 0 | 0 | 49 |
| Completed | 0 | 0 | 48 |
| Not completed | 0 | 0 | 1 |
| Withdrew: Withdrawal of consent (not due to ae) | 0 | 0 | 1 |
MRI scans assessed semi-quantitatively via a standardized chest MRI scoring system. Each participant had 6 lobes scored using 7 scoring parameters:1) Bronchiectasis/wall thickening 2) Mucus plugging 3) Abscesses/sacculations 4) Consolidations 5) Special findings 6)Mosaic pattern 7) Perfusion abnormalities. For each of 7 parameter, there were scores of 6 lobes (score of each lobe : 0= normal value, 1 = \<50% of lobe involved and 2 = \>=50% of lobe involved). MRI global score was calculated as sum of parameters 1 to 7. MRI total score is ranged from 0-84. Higher score indicate more lobe involvement.
| score on a scale | Part 1: Placebo | Part 1: LUM/IVA |
|---|---|---|
| Part 1: Absolute Change From Baseline in MRI Global Chest Score at Week 48 | -0.3 ± 6.1 | -1.7 ± 6.6 |
LCI2.5 represents the number of lung turnovers required to reduce the end-tidal inert gas concentration to 1/40th of its starting value.
| lung clearance index | Part 1: Placebo | Part 1: LUM/IVA |
|---|---|---|
| Part 1: Absolute Change in Lung Clearance Index2.5 (LCI2.5) Through Week 48 | 0.32 (-0.20 to 0.84) | -0.37 (-0.85 to 0.10) |
The z-score is a statistical measure to describe whether a value was above or below the standard. A z-score of 0 is equal to the standard. Lower numbers indicate values lower than the standard and higher numbers indicate values higher than the standard.
| z-score | Part 1: Placebo | Part 1: LUM/IVA |
|---|---|---|
| Part 1: Absolute Change in Weight-for-age Z-score at Week 48 | -0.07 (-0.24 to 0.11) | 0.13 (-0.01 to 0.27) |
The z-score is a statistical measure to describe whether a value was above or below the standard. A z-score of 0 is equal to the standard. Lower numbers indicate values lower than the standard and higher numbers indicate values higher than the standard.
| z-score | Part 1: Placebo | Part 1: LUM/IVA |
|---|---|---|
| Part 1: Absolute Change in Stature-for-age Z-score at Week 48 | 0.10 (-0.04 to 0.24) | 0.09 (-0.05 to 0.22) |
BMI was defined as weight in kilogram (kg) divided by squared height in meters (m\^2). The z-score is a statistical measure to describe whether a value was above or below the standard. A z-score of 0 is equal to the standard. Lower numbers indicate values lower than the standard and higher numbers indicate values higher than the standard.
| z-score | Part 1: Placebo | Part 1: LUM/IVA |
|---|---|---|
| Part 1: Absolute Change in Body Mass Index (BMI)-For-age Z-score at Week 48 | -0.24 (-0.55 to 0.07) | 0.20 (-0.02 to 0.41) |
Collected over From Day 1 up to Week 98 (Part 1: From Day 1 up to Week 48; Part 2: From Week 48 up to Week 98). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Placebo | 0/16 (0%) | 2/16 (12.5%) | 16/16 (100%) |
| Part 1: LUM/IVA | 0/35 (0%) | 7/35 (20%) | 33/35 (94.3%) |
| Part 2: Overall LUM/IVA | 0/49 (0%) | 12/49 (24.5%) | 41/49 (83.7%) |
| Event | Part 1: Placebo | Part 1: LUM/IVA | Part 2: Overall LUM/IVA |
|---|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 1/16 | 3/35 | 3/49 |
| Lung infiltrationRespiratory, thoracic and mediastinal disorders | 1/16 | 0/35 | 0/49 |
| Sedation complicationInjury, poisoning and procedural complications | 0/16 | 0/35 | 2/49 |
| HaematemesisGastrointestinal disorders | 0/16 | 1/35 | 0/49 |
| IntussusceptionGastrointestinal disorders | 0/16 | 1/35 | 0/49 |
| ConstipationGastrointestinal disorders | 0/16 | 1/35 | 0/49 |
| PneumoniaInfections and infestations | 0/16 | 1/35 | 0/49 |
| Coeliac diseaseGastrointestinal disorders | 0/16 | 0/35 | 1/49 |
| Distal intestinal obstruction syndromeGastrointestinal disorders | 0/16 | 0/35 | 1/49 |
| VomitingGastrointestinal disorders | 0/16 | 0/35 | 1/49 |
| Event | Part 1: Placebo | Part 1: LUM/IVA | Part 2: Overall LUM/IVA |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 8/16 | 22/35 | 19/49 |
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 9/16 | 15/35 | 11/49 |
| RhinitisInfections and infestations | 6/16 | 9/35 | 8/49 |
| CoughRespiratory, thoracic and mediastinal disorders | 5/16 | 10/35 | 11/49 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 4/16 | 0/35 | 8/49 |
| Abdominal painGastrointestinal disorders | 2/16 | 7/35 | 6/49 |
| PyrexiaGeneral disorders | 3/16 | 6/35 | 2/49 |
| Upper respiratory tract infectionInfections and infestations | 3/16 | 1/35 | 2/49 |
| Abdominal pain upperGastrointestinal disorders | 2/16 | 1/35 | 2/49 |
| VomitingGastrointestinal disorders | 2/16 | 2/35 | 4/49 |
Baseline population included all randomized participants who have received at least 1 dose of study drug.
| Age, Continuous(years) | Part 1: Placebo | Part 1: LUM/IVA | Total |
|---|---|---|---|
| Mean | 4.2 ± 1.0 | 4.2 ± 1.0 | 4.2 ± 1.0 |
| Sex: Female, Male(Participants) | Part 1: Placebo | Part 1: LUM/IVA | Total |
|---|---|---|---|
| Female | 7 | 11 | 18 |
| Male | 9 | 24 | 33 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: Placebo | Part 1: LUM/IVA | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 16 | 35 | 51 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part 1: Placebo | Part 1: LUM/IVA | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 16 | 35 | 51 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Magnetic Resonance Imaging (MRI) Global Chest Score(score on a scale) | Part 1: Placebo | Part 1: LUM/IVA | Total |
|---|---|---|---|
| Mean | 21.4 ± 9.3 | 17.6 ± 9.7 | 18.8 ± 9.6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2018 to primary completion in Oct 2020, 25 months.
Results were first posted in Dec 2021, 1 year 1 month after primary completion.
Of 40 industry-sponsored phase 2 interventional studies under Cystic Fibrosis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's 25 months is above that.
Counting every sponsor, half of 57 studies reached it within 21 months; a quarter within 9 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lumacaftor · Ivacaftor
Vertex Pharmaceuticals Incorporated →